Northern Light Mercy Hospital becomes newest member of the Dana-Farber Cancer Care Collaborative

Posted date

Dana-Farber Cancer Care Collaborative has announced that Northern Light Mercy Hospital (Portland, ME) is the newest member.

As a Dana-Farber Cancer Care Collaborative member, Mercy Hospital now has access to virtual consults and second opinions, support and education for physicians and nurses, and streamlined access to Dana-Farber specialists in Boston for patients with complex cancers.

As part of the membership process, Mercy Hospital was required to meet a wide range of standards and best practices in adult oncology. Dana-Farber Cancer clinicians and specialists conducted an extensive review of Mercy Hospital’s outpatient adult medical oncology practices and procedures, including patient safety protocols, nursing and pharmacy practices, chemotherapy administration, and information systems. 

"We are very pleased to welcome Northern Light Mercy Hospital as a new member of the Dana-Farber Cancer Care Collaborative and look forward to our work together. The Collaborative furthers our mission of helping to relieve the burden of cancer for as many people as possible. We do this by conducting research to develop new and better therapies, providing expert and compassionate care for patients, and extending our expertise and working with other carefully selected care providers, such as Northern Light Mercy Hospital," said Laurie H. Glimcher, MD, President and CEO, Dana-Farber Cancer Institute.

"We are excited to bring the renowned expertise of Dana-Farber Cancer Institute closer to home for our patients," said Charlie Therrien, president of Mercy Hospital. “Through this collaboration, our patients can be assured that our cancer care is validated by one of the world’s leading cancer centers.”

The Collaborative helps disseminate the latest and most effective, evidence-based best practices and standards to member hospitals and physician practices. Members also take advantage of ongoing consultations and access to support services, such as tumor board conferences and physician lectures.

Media Contacts

If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email

The Media Team cannot respond to patient inquiries. For more information, please see Contact Us.